Archive · 31 Jul 2025
Sun Pharma Q1: Profit Down 20% Due to Exceptional Items
Sun Pharma, a drug company, announced its financial results for the first quarter.
Although revenue went up due to strong sales in India and from new medicines, the company's profit decreased by 20% because of settlement costs from a pricing lawsuit in the US and a loss from stopping a drug trial.
Sales in India grew strongly, and the company saw good results from its new medicines, particularly in the US.
Excluding the one-time charges, the company's profit actually increased.
Overall, Sun Pharma saw gains but faced some financial setbacks due to specific issues.
Sun Pharma's Q1 FY26 net profit decreased 20% to ₹2,279 crore.
Consolidated revenue increased 9.4% to ₹13,851 crore.
India formulation business grew 13.9% to ₹4,721 crore.
US formulation sales rose 1.4% to $473 million.
Adjusted net profit, excluding exceptional items, rose 6% to ₹2,996 crore.
- Who
- Sun Pharmaceutical Industries Ltd.
- What
- Sun Pharma's Q1 FY26 financial results.
- When
- The quarter ended June 30, 2025, with results announced on Thursday.
- Where
- Focus is on India and US markets.
- Why
- To assess the company's financial performance.
Financial Highlights
Financial Impact
Revenue vs. Profit
Financial Highlights
Revenue increased by 9.4%.
Financial Impact
Net profit decreased by 20%.
- Net Profit
- ₹2,279 crore
- Revenue
- ₹13,851 crore
- India Formulation Business Growth
- 13.9%
- US Formulation Sales
- $473 million
- Adjusted Net Profit
- ₹2,996 crore
- Ebitda Margin
- 31.1%
Sources
Sun Pharma Q1 preview: High domestic, global specialty biz growth to boost revenue
Sun Pharma Q1 Results: US sales meet expectations; one-off drags profit
Sun Pharma Q1 Results: Net profit declines 20% to ₹2,279 crore; revenue up 9%
Sun Pharma has no plans to shift manufacturing to US, says management
Sun Pharma net profit falls on US antitrust settlement, drug impairment costs
